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Resumo 
 
 Polimorfismos em genes que codificam enzimas metabolizadoras de fármacos 
(EMFs) são os maiores influenciadores da variabilidade interindividual no que diz 
respeito à resposta a fármacos. Dentro das EMFs, o citocromo P450, família 2, 
subfamília D, polipéptido 6, CYP2D6, é uma das mais importantes pois é responsável 
pela metabolização de 25 a 30% de todos os fármacos prescritos, incluindo 
antidepressivos, antipsicóticos, antiarrítmicos, bloqueadores β, anti-tumorais, entre 
outros. A atividade enzimática do CYP2D6 varia bastante entre indivíduos, 
principalmente devido a variações genéticas no gene codificante, resultando em 
consequências clínicas significativas para o metabolismo de fármacos e também riscos 
individualizados no que toca a efeitos adversos ou alterações na resposta pretendida. 
Apesar de várias populações já terem sido estudadas relativamente ao CYP2D6, ainda 
existem algumas que foram escassamente analisadas, como o caso dos ciganos 
europeus. 
 Os ciganos são um caso de estudo populacional interessante que ainda está 
pouco estudado em vários aspetos. Durante o seu período migratório, era normal 
ocorrer a fragmentação em grupos mais pequenos, mantendo na mesma as suas 
práticas endógamas. Do ponto de vista genético, isto leva a elevados efeitos de deriva 
genética, diversidade genética reduzida, elevado linkage disequilibrium e fluxo genético 
limitado entre grupos. 
 Assim, e atendendo à escassez de estudos farmacogenéticos nos ciganos, neste 
estudo pretendemos caracterizar a população de ciganos portugueses, através do 
estudo de Single Nucleotide Polymorphisms (SNPs) com interesse farmacogenético, e 
para avaliar se estes apresentam diferenças no que toca à resposta a fármacos, 
comparativamente à restante população portuguesa. Nesse sentido, 56 amostras de 
ciganos portugueses foram analisadas por reação de SNaPshotTM, desenhado e 
otimizado para detetar 11 SNPs dentro do gene CYP2D6, que estão associados a 
alterações na resposta a fármacos. Para comparação de resultados, foram usados 
dados anteriormente publicados para a restante população portuguesa, bem como 
dados de outras populações de todo o mundo, para inserir os nossos resultados num 
contexto mundial. 
 Das variações estudadas, apenas uma não se encontrava de acordo com o 
equilíbrio de Hardy – Weinberg, mesmo após a correção de Bonferroni, que foi a posição 
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4180 G>C. Comparativamente à restante população portuguesa, os ciganos 
apresentam uma frequência mais elevada do CYP2D6*4, um dos alelos que apresenta 
atividade nula. Relativamente aos perfis metabólicos teoricamente definidos, foram 
encontradas diferenças entre os ciganos e os restantes portugueses, principalmente nos 
perfis Poor Metabolizers (PM), Intermediate Metabolizers (IM) e Extensive Metabolizers 
(EM).  
 Contudo, apesar de ter sido aplicada uma técnica de considerável resolução, em 
termos de SNPs, estudos futuros são necessários para aprofundar os resultados 
obtidos, preferencialmente com análise conjunta bioquímica da atividade enzimática. 
Para além de caracterizar melhor a população cigana portuguesa, será também 
importante ter dados de outras populações ciganas europeias, para que o conhecimento 
sobre os ciganos europeus permita extrair mais inferências relevantes do ponto de vista 
da farmacogenética. 
 Com o desenvolvimento deste estudo, contribuímos para um aprofundamento da 
caraterização da população cigana, ajudando a promover o conhecimento do ponto de 
vista farmacogenético, relativo ao CYP2D6, bem como a realçar a importância da 
farmacogenética no cenário clínico. 
 
Palavras – Chave: Farmacogenética, Enzimas Metabolizadora de Fármacos, CYP2D6, 
SNP, População Cigana 
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Abstract 
  
 Polymorphisms in genes coding for drug-metabolizing enzymes (DME) are major 
players in interindividual variability in drug response. Among DME, cytochrome P450 
family 2, subfamily D, polypeptide 6, CYP2D6, is one of the most important, because it 
is involved in metabolism of 25% to 30% of all prescribed drugs, including 
antidepressants, antipsychotics, anti-arrhythmics, β-blockers, cancer 
chemotherapeutics, among others. The enzymatic activity of CYP2D6 varies widely 
among individuals, mainly due to functional genetic variations at the encoding gene, 
resulting in significant clinical consequences for drug metabolism and individual risk of 
adverse events or drug efficacy. Although many populations have been studied 
regarding the CYP2D6, there are still populations scarcely studied, such as the Roma 
from Europe.  
 The Roma represent an interesting population case study that is still understudied 
in many aspects. During the Gypsy diaspora, it was normal the occurrence of group 
fragmentation into smaller communities, but still maintaining endogamous practices. 
From a genetic point of view, this leads to high genetic drift effects, reduced genetic 
diversity, high linkage disequilibrium and limited gene flow between these groups.  
Therefore, due to these traits and to the scarcity of Pharmacogenetic studies in 
this population, in this present study, we intended to characterize the Portuguese Roma 
for Single Nucleotide Polymorphisms (SNPs), relevant from the Pharmacogenetics point 
of view, to evaluate if the Roma show any peculiarity regarding drug response, in 
comparison with the host population. In that sense, 56 samples from Portuguese Roma 
were analysed by SNaPshotTM reaction, designed and optimized to detect 11 SNPs 
located within the CYP2D6 gene, known to influence drug response. For comparative 
analysis, data from previous studies in the Portuguese host population was used, as well 
from several populations around the world, to put the data obtained in a worldwide 
context. 
For the variations studied, only one SNP revealed significant deviation from the 
Hardy – Weinberg expectation, even after the Bonferroni correction, which was the 4180 
G>C. Comparatively to the Portuguese host population, the Roma showed some 
differences, especially an increased frequency of the CYP2D6*4, an allele implying null 
enzymatic activity. Regarding the theoretical metabolic profiles, differences were found, 
especially the IM and PM profiles. 
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Even though we studied a set of SNPs considered to be of high resolution, further 
studies are needed to deepen the results here obtained, preferably with the joint analysis 
of biochemical assessment of enzymatic activity. Also, new studies are needed, not only 
in the Portuguese host population, but also in other European populations, with a larger 
number of SNPs, so that the knowledge regarding these populations and further 
comparative analysis can allow to extract more inferences relevant from the perspective 
of Pharmacogenetics. 
With the development of the present study, we have contributed to deepening the 
characterization of Roma populations, helping to further the knowledge from the 
pharmacogenetic point of view regarding the CYP2D6, as well as to enhance the 
importance of Pharmacogenetics in the clinical setting. 
 
Keywords: Pharmacogenetics, Drug-Metabolizing Enzymes, CYP2D6, SNP, Roma 
Population 
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I. INTRODUCTION 
 
1. Pharmacogenetics 
The term pharmacogenetics is often used to describe a relatively new field of 
genetics that covers the study of how different gene variants affect drug response or, by 
other words, the study of the effect of heredity in human’s drug response. Nowadays, 
pharmacogenetics is largely contributing to the emergence of personalised medicine, 
also called individualized or precision medicine that aims, in its narrow sense, to 
customize health care, with decisions and treatments tailored to each patient (1).  
Primordial observations in this field go back to 510 B.C., when Pythagoras 
described that some individuals, after ingesting fava beans, showed dangerous 
reactions, when the rest of them did not (2).  
In the 1950s, the introduction of therapeutic drug monitoring, generally defined 
as the clinical practice of measuring specific parameters at regular intervals that, with 
appropriate interpretation, directly influence drug prescribing procedures (3), 
represented the first systematic approach to individualize the treatment of patients that 
still has significant value in assessing drug therapy, particularly in psychiatry and severe 
infections (4, 5). With the unravelling of the structure of DNA and subsequent 
development of molecular biology, a new era was open to study the genetic bases of 
phenotypes associated with variability in drug response. Since then, it became 
increasingly well documented that genetic variations was an important determinant of 
interindividual variability in drug response (6). 
The grand majority of genetic variations influencing drug response belong to the 
class of Single Nucleotide Polymorphisms (SNPs), which are variations in single 
nucleotides of the DNA sequence characterized by the occurrence in at least 1% of the 
population. SNPs are the most common polymorphisms in the human genome, 
accounting to more than 90% of the human genetic variations. Although most SNPs do 
not present effect on gene function, some have profound impact on the function of 
associated genes, whether the SNPs occur in the coding regions or at a significant 
distance from the transcription starting site of the gene (6). When such kind of variations 
are encountered in genes that encode enzymes responsible for absorption, distribution, 
metabolism or excretion of drugs, enzyme activity can be disturbed, leading to 
undesirable response to drugs which can be potentially fatal. Therefore, it is important to 
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study these polymorphisms, not only on a pharmacological perspective (which can, in a 
near future, lead to individualized treatments), but also on a forensic viewpoint, where it 
can be applied, together with Toxicology, to solve cases where the cause of death is 
inconclusive (7, 8). 
  
 
1.1. Pharmacogenetics applications  
 
 With the development of health care and the rise of its costs, there has never 
been a greater need to reduce waste. In this context, ineffective treatments and adverse 
drug effects must urgently be minimized. Nowadays, the path to maximizing benefit and 
reduce negative effects seems to reside in stratifying patient populations into subgroups 
taking into account the patient individuality in response to a certain treatment since it is 
well known that an individual’s response to a drug is affected by personal factors such 
as age, gender and genetics. Before a drug can be used in the clinical practice it must 
be subjected to clinical trials conducted to collect data demonstrating its safety and 
efficacy. Typically, however, clinical trials only give information regarding the “average 
patient”, not taking into account that every individual has different backgrounds which 
can lead to a wide variability in drug response. It is now widely considered that 
pharmacogenetics must have a critical role in the clinical trials, specifically in the early 
stages of the treatment, by assisting to define the number of patients to analyse, to 
predict the efficiency of the therapy and to identify subgroups in which a distinct treatment 
is needed. Besides the contribution to the success of clinical trials, pharmacogenetics is 
also crucial in the clinical setting, where the use of genetic tests can give a prediction of 
drug response regarding a certain person before the treatment is started, allowing thus 
saving in expensive therapeutics that would probably not work and at the same time 
preventing levels of toxicity that sometimes cannot be measured by traditional methods. 
This happens, for instance, in oncological treatments, where the use of genetic tests can 
lead to the identification of various mutations in driver oncogenes that reduce the binding 
capacity of the drug and consequently low therapeutic success and/or resistance (5, 9-
11). 
 Although pharmacogenetics has been preponderantly associated with the 
advantages it can provide in terms of clinical applications, it is also gaining ground in 
forensic sciences. Forensic pharmacogenetics is a relatively new and growing area of 
research. It is being increasingly applied in post-mortem cases, as an adjunct in the 
determination of the cause of death, namely through the analysis of certain genetic 
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variants in specific genes that encode proteins involved in drug metabolism. 
Pharmacogenetic approaches might help to infer if high levels of a specific drug detected 
in a corpse can be the cause of death due to overdose or due to inefficient metabolism 
caused by the presence of a certain genetic variation. As a matter of fact, acute drug 
intoxication is a major cause of unnatural deaths in occidental countries, usually requiring 
a forensic investigation to determine the reasons of the intoxication and consequently 
the likely explanation for the death. Among the most common drugs found in intoxication 
cases are psychiatric drugs and analgesics such for instance tramadol, an opioid 
analgesic commonly prescribed in the treatment of postoperative, dental, cancer, 
neuropathic and acute musculoskeletal pain. Since the enzyme CYP2D6 plays a 
predominant role in tramadol metabolism, and given that null variants in the encoding 
gene associated with enzyme inactivation can cause acute intoxication in patients 
administrated with inaccurate doses of the drug, CYP2D6 is being one of the most widely 
studied genes in forensic pharmacogenetics (7, 12).  
 
 
1.2. Pharmacogenetics Challenges 
 
 Despite being well recognised the importance of pharmacogenetics, which 
continues to grow, particularly in the clinical practice and in the pipeline of drug 
development, pharmacogenetics also faces some setbacks. For instance, the evaluation 
of the clinical cost – effectiveness of a genetic test is critical. Even though there are 
studies evidencing the advantages of pharmacogenetic testing, in order to obtain valid, 
accurate and relevant cost-effectiveness estimates, reliable economic studies are 
required and this proves to be a challenge because often there is no hard clinical 
evidence regarding the effects of the test on the clinical utility (4). Furthermore, the 
information is not available for every genetic variant of pharmacogenetic relevance. 
Differences in costs can be substantial between countries, or even laboratories, and thus 
it is important to take this into account in scenario analysis, as well as the sensitivity and 
specificity of pharmacogenetics tests, which also represent another challenge since they 
can vary in function of the different ethnicities studied or genetic variations analysed (4).  
 To perform economic evaluations of pharmacogenetic tests is necessary to rely 
in relevant clinical data, which are often difficult to obtain. Until recently, evidence has 
been mainly provided by means of conventional clinical trials, but there is now a 
movement toward using observational studies instead of randomized trials. The Clinical 
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Pharmacogenetics Implementation Consortium (CPIC), based in the United States, 
promotes reviewed guidelines on how to use pharmacogenetics tests results to improve 
treatments based on evidence according to patients’ medical records (13). Though the 
development of CPIC guidelines was a good step toward the implementation of 
pharmacogenetics tests in routine clinical practice, some fear that the assessment of 
pharmacogenetics might be obstructed because these guidelines “bypass traditional 
data requirements needed to support the use of a new intervention and move straight to 
producing recommendations for its use in clinical practice” (13). In other words, some 
people claim that the production of guidelines without information about, for instance, its 
effectiveness in a certain population, such as the one we can obtain through randomized 
trials, may still give insufficient information regarding cost effectiveness, not allowing 
policy makers to make reimbursement decisions easier. Therefore, there is the need to 
boost the development of a strong evidence - base for pharmacogenetics by alternative 
means that can satisfy the requirements of health care payers (4, 9, 13).  
 
 
2.  Drug Metabolism 
   
 Xenobiotics are foreign chemical substances which are not normally produced or 
expected to be within an organism. When these substances enter the human body, they 
pass through several biochemical transformations in order to be transformed in other 
metabolites, less harmful, minimizing thus aggression to the organism. The process by 
which these biochemical transformations occur is commonly known as xenobiotic or drug 
metabolism. One of the most important end results of the biochemical reactions that 
transform the foreign elements in products easier to be eliminated, is to avoid 
accumulation in the organism, thus preventing possible toxic reactions. Although drug 
metabolism typically inactivates drugs, they can also convert an inactive drug (called 
prodrug) into an active one, an active drug into an active or toxic metabolite, or an 
unexcretable drug into an excretable form (14, 15). 
 To process these foreign substances, many biochemical transformations occur 
that require the machinery of several enzymes, known as drug metabolizing enzymes or 
xenobiotic enzymes (DMEs or XMEs), responsible by different steps in the metabolic 
pathways. While DMEs can be synthetized in many organs, the most active one is the 
liver, where the grand majority of these enzymes are produced. Accordingly, it is also in 
the liver that many drugs begin to undergo extensive biotransformation. Its effectiveness 
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in the liver might be very high, so that only a small portion of the drug reaches the blood 
stream. This process - known as first pass effect or presystemic metabolism – whereby 
the concentration of a drug is greatly reduced before it reaches the systemic circulation, 
greatly influences the bioavailability of a drug  (16, 17).  
 Drug metabolism is divided in three phases: phase I, in which DMEs introduce 
reactive or polar groups into xenobiotics, mainly by oxidation, hydroxylation and 
hydrolysis (Figure 1, PHASE 1); phase II, where these modified compounds are then 
conjugated into polar compounds, such as glutathione (GSH) and glucuronic acid (Figure 
1, PHASE 2); and phase III, when the xenobiotic conjugates are further metabolized and 
excreted (Figure 1, PHASE 3). Although these phases can occur separately, they 
normally take place in succession. Whatever the process and phase of drug metabolism, 
the rate of biotransformation reactions is not the same for every individual, since 
differences in genetic profiles and environmental factors, such as age, gender, drinking 
and smoking habits, can account to wide intra-individual variability  (17-19).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Schematic representation of drug metabolism in the human body. The 
Drug Metabolism is divided in 3 Phases: Phase 1, where occurs the 
biotransformation of the xenobiotics; Phase 2, where occurs the synthesis of these 
xenobiotics; Phase 3, where occurs the excretion of the metabolites resultant from 
the biodegradation of the xenobiotics through the different pathways. 
                                                                                                                                                  FCUP 20 
                                                  Updating the study of pharmacogenetic polymorphisms in the Portuguese Roma 
2.1. Phase I of Drug Metabolism 
 
 Drug Metabolizing Enzymes (DMEs) play central roles in the metabolism, 
elimination and/or detoxification of xenobiotics or exogenous compounds introduced into 
the body (17). In the phase I of Drug Metabolism, a variety of enzymes act to introduce 
reactive and polar groups into their substrates. Phase I reactions may occur by oxidation, 
reduction, hydrolysis, cyclization and decyclization, all occurring predominantly in the 
liver. For instance, through phase I oxidation, which involves the conversion of a C-H 
bond to a C-OH, a pharmacologically inactive product (prodrug) can be converted into a 
pharmacologically active compound, or also a nontoxic molecule can be transformed in 
a toxic one as illustrated by phase I metabolism of acetonitrile to glycolonitrile, which 
rapidly dissociates into formaldehyde and hydrogen cyanide, both of which are toxic (14, 
17, 20).  Most of the enzymes involved in phase I reactions belong to the large family of 
cytochrome P450 (CYP450) enzymes, including the CYP2D6. 
 
2.1.1. Cytochrome P450 system   
 
 Cytochrome P450 (CYP450) is the generic name given to a large family of highly 
versatile enzymes involved in drug metabolism and response (15). Besides the 
preponderant role in xenobiotic metabolism, they also have important functions in other 
processes, including steroid and cholesterol biosynthesis, fatty acid metabolism and the 
maintenance of calcium homeostasis. CYP450 enzymes can be found abundantly in the 
endoplasmic reticulum of liver cells, but also in the gastrointestinal tract, lung and kidney, 
though showing lower levels of expression (17, 21). 
 There are 57 active CYP genes in the human genome, which are divided into 18 
families, accordingly with their amino acid sequence similarities. The first three families 
(CYP 1-3) are mainly responsible by the metabolism of exogenous substances, such as 
drugs, whereas the CYP families with higher numbers are usually more involved in the 
metabolism of endogenous substances. CYP enzymes participate in  75-80% of all 
phase I – dependent metabolism and for 65-70% of the clearance of clinically used drugs 
(22).  The CYP isoenzymes are named according to specific standards, which can be 
exemplified using the CYP2D6: CYP is the abbreviation for cytochrome P450, the 
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number “2” designates the family, the letter “D” stands for the subfamily and the number 
“6” represents a specific gene (23). 
 From all the active elements of the CYP family, CYP3A4 is responsible for about 
50% of all CYP-dependent drug metabolism. In the encoding gene, more than 20 
common genetic variants have been identified, most of them resulting in decreased 
enzymatic activity, which substantially contribute to the high variability among individuals 
regarding CYP3A4 – mediated drug metabolism, although other factors concur for such 
variability. On the other hand, nearly 40% of the metabolism of all clinical used drugs is 
carried out by CYP2C19 and CYP2D6 enzymes, whose genes are as well highly 
polymorphic. Other members, like CYP1A2, CYP2A6 and CYP2B6, that  contribute 
greatly to xenobiotic metabolism, are also encoded by highly polymorphic genes (22). 
 Due to the polymorphic nature of the CYP enzymes, they are usually associated 
with the phenotypic variation elicited in drug-treated subjects, which is much dependent 
on levels of enzymatic activity. Accordingly, individuals are often described to be 
ultrarapid, extensive, intermediate and poor metabolisers (Figure 2). Ultrarapid 
metabolisers (UM), usually carry more than two copies of alleles conferring together 
greater than normal enzymatic activity; intermediate metabolisers (IM) are heterozygous 
for one defective and one functional allele or for 2 partially defective alleles; poor 
metabolisers (PM) carry two defective alleles and extensive metabolisers (EM) carry two 
alleles with normal function of the CYP enzyme. Therefore, depending on the phenotype 
of each individual, the drug metabolism can vary, leading to alterations in drug 
effectiveness (15, 22, 24).  
 
 
 
 
 
 
 
 
Figure 2 - Representation of the different phenotypes in a population. Ultrarapid Metabolizers present more 
than 2 copies of the gene, Extensive Metabolizers present 2 copies of the normal gene, Intermediate 
Metabolizers present 1 copy with normal function and 1 with reduced function r both with reduced function and 
Poor Metabolizers present no functional copies of the gene.  Adapted from Krammer et al. (2009) 
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2.1.1.1. Cytochrome P450 2D6 – CYP2D6 
 
 So far, CYPD26 has been one of the most studied pharmacogenes, because it 
presents the greatest impact of genetic polymorphism among all major CYP enzymes, 
due to its wide spectrum of genetic variants (from null alleles to several-fold gene 
amplification), comparably little influence by environmental and non - genetic factors, 
and its extraordinarily broad substrate selectivity (15).  
CYP2D6 contributes to the metabolism of up to 25% of all clinically used drugs 
from virtually all therapeutic classes (25). It is involved in the Phase I of the drug 
metabolism, working through the various reactions described in point 2.1. According to 
He et al. (26), CYP2D6 acts on more than 160 drugs, including tricyclic antidepressants, 
serotonin-selective reuptake inhibitors, opioids, and antiemetics, but also antiarrythmics, 
β-blockers, antihistamines, and antiviral agents. In Table 1 are listed the most common 
clinically used drugs metabolized by CYP2D6, as well as some known drugs that may 
function as inhibitors of CYP2D6 activity. 
 
Table 1 – Drugs metabolized by the CYP2D6 gene. Adapted from Department of Medicine, Indiana University’s website 
(27) 
 
Beta-Blockers Antidepressants Antipsychotics Others
Carvedidol Amitriptyline Haloperidol Aripiprazole
S -  metopropol Clomipramine Risperidone Atomoxetine
Propafenone Desipramine Thioridazine Codeine
Timolol Duloxetine Dextromethorphan
Fluoxetine Doxepine
Imipramine Flecainide
Paroxetine Mexiletine
Ondansetron
Oxycodone
Tamoxifen
Tramadol
Venlafaxine
Diphenhydramine
SUBSTRATES
INHIBITORS
Bupropion
Fluoxetine
Paroxetine
Quinidine
Duloxetine
Amiodarone
Cimetidine
Aripiprazole
Terbinafine
Chlorpheniramine
Clomipramine
Doxepin
Haloperidol
Methadone
Ritonavir
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The CYP2D6 gene is located on chromosome 22q13.1, in a region containing the 
entire CYP2D gene cluster, which besides CYP2D6 also harbours 2 pseudogenes, 
CYP2D7 and CYP2D8P (Figure 3). The pseudogene CYP2D7 is expressed as mRNA in 
the liver, but due to an insertion in the first exon disrupting the reading frame, protein 
production is null. In the case of the CYP2D8P, it’s a true pseudogene which has 
accumulated several gene-disrupting mutations (15). The expression of CYP2D6 is 
mostly confined to the liver, although low levels of protein have been shown in 
extrahepatic tissues like the gastrointestinal tract and in the human brain. 
 
 
 
 CYP2D6 gene contains 9 exons spanning ~4,4 kb, and encodes a protein with 
497 amino acids, although other alternatively spliced transcripts resulting in different 
isoforms have been reported 
(http://grch37.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG0000010
0197;r=22:42522501-42526908).  There are currently more than 100 distinct alleles and 
a grand number of rare variants described in the Human Cytochrome P450 (CYP) Allele 
Nomenclature Database - (http://www.cypalleles.ki.se/cyp2d6.htm). Many result in 
absent or non – functional protein (i.e. CYP2D6*3, *4, *5, *6), in decreased (i.e. 
CYP2D6*9, *10, *17, *41) or increased (i.e. CYP2D6*1XN, *2XN) expression. Other 
alleles present normal function (i.e. CYP2D6*1 or Wild type and CYP2D6*2) (15, 28-30).  
The majority of these alleles result from sequence variations like SNPs and small 
In/Dels within the CYP2D6 gene.  However, structural variants are also commonly 
Figure 3 - Schematic representation of the CYP2D6 gene cluster. In dark green, purple and light green, we have the representation of the 
CYP2D8, CYP2D7 and CYP2D6, respectively. The CYP2D7 spacer is located between a common 0,6 kb repeat (marked as red) and the 2,8 
kb REP 7 sequence, a repetitive segment specific of the CYP2D7 pseudogene (marked as grey). The 0,6 kb repeat is found downstream of 
all genes. The 2,8 kb REP 6 sequence, a repetitive segment specific of the CYP2D6 gene, is marked as a blue. Adapted from Krammer et al. 
(2009) and Gaedigk et al. (2007)   
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detected in the entire CYP2D locus, because the locus is very prone to unequal crossing 
over between the highly homologous regions it contains. Accordingly, complete or partial 
deletions and duplications were shown to occur often, meaning thus that copy number 
variation involving the CYP2D6 gene is quite common. In addition, other products of 
recombination within the CYP2D cluster account to the diversity at the locus. It follows 
that both sequence and structural variations may originate alleles conferring no, 
decreased, normal or increased function, which in the whole are highly responsible for 
the wide range of levels of enzymatic activity across individuals. One of the extremes 
contains the so-called poor metabolizers, individuals with two non-functional alleles who 
cannot metabolize or bioactivate drugs through CYP2D6, while the other extreme 
contains the ultra-rapid metabolizers, who are those carrying at least one increased 
function allele (i.e., two or more copies of a functional allele on one chromosome) in 
addition to a normal-function allele. The groups of poor and ultra-rapid metabolizers are 
at the highest risk for experiencing dose-related adverse events or treatment failure, 
depending on the drug administered (25).  
Given the clinical relevance of CYP2D6, numerous genotyping strategies have 
been developed (28, 29) with the main goal of be able to predict the metaboliser 
phenotype of each tested individual. However, the design of genotyping assays for 
CYP2D6 is very challenging, once is necessary to deal with the major problem of 
detecting not only the multitude of alleles defined by sequence variation in a gene that is 
highly polymorphic, but also the structural variants that might be present in combination 
with any other CYP2D6 allele. For this reason, even with the most accurate genotyping 
methods, much caution is needed to make phenotypic predictions from genotypic data 
(29). Indeed, the reliability of phenotype prediction from genotype data is strongly 
influenced by the alleles interrogated in the typing assays. Unless using complete 
resequencing approaches, many alleles altering enzymatic activity might escape 
detection, resulting in frequencies of default alleles misleadingly overestimated (25). 
This is a problem that cannot be overcome even following the guidelines that 
have been developed by the Clinical Pharmacogenetics Implementation Consortium 
(https://cpicpgx.org/) to translate genotypes into predicted phenotypes (31). 
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2.1.1.2. Worldwide Genetic Distribution  
   
 
It is well documented that most genetic polymorphisms in drug metabolizing 
enzymes reveal substantial differences in allele frequencies across major human 
populations. CYP2D6 is no exception, and shows allele frequencies highly varying in 
world populations, which consequently implies extensive variation in the distribution of 
the phenotypic response to drugs metabolized by CYP2D6 among worldwide 
populations. 
Previous genetic studies revealed that CYP2D6 diversity was far greater within 
populations than between groups of populations and that null or low-activity variants 
occurred at considerably high frequencies in various regions of the world, although 
specific allelic variants are present at very distinct frequencies among world populations, 
whereas other are restricted to certain population groups (25). 
Furthermore, the macrogeographical spatial patterns of diversity at CYP2D6 
revealed to be clinal, and very similar to those shown by neutral markers, indicating that 
CYP2D6 diversity was modelled by the same factors that randomly affected neutral 
genomic variation (32). It is known that geography was the main factor influencing 
genetic differentiation among humans. Both physical distances and geographic barriers 
limits human communication and interaction, which has led to a global genetic 
substructure that largely follows geographic clines.  
However, populations may be genetically structured, when composed by more 
than one subpopulation that tend to maintain endogamous practices. These 
subdivisions, often corresponding to ethnic groups, are not mainly influenced by 
geography, but instead by social factors, including religion, culture, language, and other 
sources of group identification, thus leading to varying degrees of genetic structure, 
depending on the extent of reproductive isolation and endogamy.  
From the genetic point of view, the Portuguese represent a homogeneous 
population that is very well integrated in the context of populations from Western Europe. 
This scenario does not take into account the Portuguese Roma, who were demonstrated 
to contribute to some level of population structure in Portugal (33). 
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3.  Portuguese Roma 
 
 The Roma, also referred to as Romani and widely known as “Gypsies” among 
English-speaking people, are a transnational ethnic group, often reputed for their 
nomadic tradition, that nowadays is mostly spread throughout Europe, Near East, 
Caucasus and the Americans. 
 The social structure of the Roma groups is heavily influenced by the traditional 
endogamy, which is the trend to marry individuals within the same subgroup, since 
marriages between non-Roma or between Roma from different groups are avoided.  
Although their history was largely lost, important insights on the issue have come 
from scarce historical records documenting the presence in countries where they have 
lived, from  linguistics, and more recently from genetics (34).  
 Most studies performed so far suggested that the original homeland of the Roma 
was India, from where they departed around the 5th and 10th century, travelling to Europe, 
reaching first the Balkans region and later migrating into multiple locations throughout 
the whole continent in such way that by the 15th century they were already present in 
Spain and Portugal (34, 35). Genetic and linguistic studies pinpointed affinities between 
Roma population and various Indian groups. Comparative linguistics studies suggested 
that North-western Indian languages, such as Punjabi or Kashmiri or Central Indian 
languages like Hindi are the most related to Romani (35, 36). Genetic studies in groups 
of European Roma, showed that all groups share high frequency of Y – chromosome 
lineages, such H1a-M82 and mitochondrial haplogroups like M5a1, M18 and M35b, 
which are usually absent in European populations, while being rather common in South 
Asian Populations, especially from Northern India (36, 37). Nevertheless, the ancestral 
group/geographic region of India from which the Roma groups have originated is still 
unclear, given the contradictory evidence provided by a recent study  that they might 
descend from southern Indian groups (34, 37). 
 The Roma populations represent an interesting case of study, especially from a 
genetic point of view, because due to their endogamous practices, limited gene flow 
between groups and past history of successive group fragmentations that occurred 
during their migration into and within Europe, they present signatures of strong genetic 
drift effects, such as reduced genetic diversity and high linkage disequilibrium (36). 
Besides, from a pharmacogenetic point of view, the Roma population is still 
understudied. Although a previous study addressing genes that influence drug response 
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has already been conducted in the Portuguese Roma Population (38), they still remain 
very poorly characterized in regard to a fraction of diversity that can have high clinical 
relevance.  
 
 
II. AIMS 
 
 In the present study we intended to assess, in the Portuguese Roma, genetic 
diversity in the CYP2D6, a gene very important from a Pharmacogenetic point of view, 
to evaluate whether this population group show any peculiarity regarding drug response, 
in comparison with the remaining Portuguese population. In order to achieve this goal, 
the following partial aims were established: 
 Search and selection of SNPs and CNVs with pharmacological relevance 
and development of PCR and minisequencing multiplex reactions 
(SNaPshotTM); 
 Genotyping of a sample of Portuguese Roma population; 
 Comparison of the results in the Portuguese Roma with those previously 
available for the Portuguese host population and other populations, to put 
the data obtained in a worldwide context. 
 
 
III. MATERIALS AND METHODS 
 
1. Samples and DNA extraction 
In this study, 56 samples from self-identified Portuguese Gypsies were analysed. All 
samples have been extracted for previous works by the Chelex®-100TM (BioRad) 
method described in Laureau et al. (39). 
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2. PCR design 
 
We first performed a thorough literature search in order to select SNPs in the 
CYP2D6 with pharmacogenetic interest. At the end, the following eleven SNPs were 
chosen: 100 C>T (rs1065852); 1023 C>T (rs28371706); 1659 G>A (rs61736512); 1707 
del. T (rs5030655); 1846 G>A (rs3892097); 2549 del. A (rs35742686); 2615 del. AAG 
(rs5030656); 2850 C>T (rs16947); 2988 G>A (rs28371725); 3183 G>A (rs59421388); 
4180 G>C (rs1135840). This set of SNPs allows the identification of the CYP2D6 
haplotypes that are widely represented in different human populations. For the sake of 
simplicity, the CYPD2D6 haplotypes are conventionally referred to as CYPD2D6 alleles 
(http://www.cypalleles.ki.se/cyp2d6.htm), among which are included some that do not 
affect enzyme function (i.e. CYP2D6*1, *2, *34, *39), and others that are associated to 
low or null metabolic activity (i.e. CYP2D6 *3, *4, *5, *6, *9, *10, *17, *41) (23, 25).  To 
obtain genotype data for these SNPs, a SNaPshotTM strategy was applied, as will be 
described in the next point.  
 
Viewing the detection of cases where CYP2D6 is deleted and the whole gene, 
primers were designed based on previous studies involving the CYP2D6 gene. For 
amplification of the whole gene, a pair of primers were designed as described in Sistonen 
et al. (2005) (28) with the exception of the forward primer, which was designed by us 
since the previous one was located in a highly polymorphic region, resulting in fragment 
A (Figure 4.c). In order to detect the presence or not of the gene deletion, a pair of 
primers described in Krammer et al. (2009) (40) was selected, resulting in the fragment 
C (Figure 4.b). Also, a PCR reaction was performed to detect cases where CYP2D6 was 
duplicated, using a pair of primers identical to the one described in Gaedigk et al. (2007) 
(29), resulting in fragment B (Figure 4.c). Also, in order to access whether there was a 
gene duplication or not, a control sample from the Human Genome Database Panel – 
Centre Étude Polymorphism Humain (HGDP-CEPH) was used. Lastly, an approach to 
amplify the whole duplicated gene in samples positive for the previous approach 
described was developed, using a set of primers identical to those described in Gaedigk 
et al. (2007) (29), resulting in fragment D (Figure 4.c). Detection of possible non-specific 
annealing was tested in BLAT (UCSC) (htts://genome.ucsc.edu/cgi-
bin/hgBlat?command=start) selecting only the human genome. In order to find out if the 
primers could form primer-dimer structures and/or hairpins, the Oligocalc program was 
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used (http://biotools.nubic.northwestern.edu/OligoCalc.html). After the in silico 
evaluation, each pair of primers was tested in individual amplifications in order to assess 
their functionality. Each one of the primers was used at a final concentration of 4 µM.  
 
 
 
 
 
 
 
 
 
The PCR reactions were performed in a final volume of 10 µL, containing 4,5 µL 
of deionized water, 1 µL of 10x Advantage® Genomic LA Buffer (Clontech), 0,4 µL of 
Expand Long Range dNTP Pack (Roche Diagnostics GmbH), 1,2 µL of each primer, 0,1 
µL of Advantage® Genomic LA Polymerase Mix (Clontech) and 1,6 µL of DNA. The 
amplification conditions were as follow: 94ºC for 3 minutes, proceeded by 5 cycles at 
98ºC for 15 sec, 63ºC for 1.30 min and 68ºC for 8 min, and another 30 cycles at 98ºC for 
15 sec, 62ºC for 1.30 min and 68ºC for 8 min and a final extension at 72ºC for 10 min. In 
the case of the specific region approach and the whole gene duplication approach, the 
Table 2 - Primers used in the PCR amplifications 
Figure 4 – Schematic representation of different CYP2D6 gene arrangements. a) Normal representation of the CYP2D6 gene cluster; b) Representation of 
a CYP2D6 gene deletion. As we can notice, comparing with a), the CYP2D6 gene is deleted and a hybrid between the CYP2D6 specific replicated region 
REP 6 and the specific replicated region of CYP2D7, REP 7, is formed, and using the primers CYP2D7_Seq B1 and CYP2D6_Rep 7R3 (Table 2), we 
obtain fragment C, indicative of a CYP2D6 gene deletion; c) Representation of duplicated event. Fragment A results from the use of primers CYP2D6_F 
and CYP2D6_R (Table 2), which were used to assess the presence of the CYP2D6 gene. Fragment B results from the use of primers CYP2D6_DUP_Fw 
and CYP2D7_DUP_Rv (Table 2), which amplifies a specific replicated region of the duplicated gene, nominated REP-DUP, which is an indicative of a 
duplication of the CYP2D6 gene. Fragment D is the result of primers CYP2D7_Fw_DUP_TOTAL and CYP2D7_DUP_Rv, amplifying the whole CYP2D6 
duplicated gene from samples positive for Fragment B. Adapted from Krammer et al. (2009) 
NAME Sequence 5' -  3 ' SIZE (Kb)
CYP2D6_F TCAGGAGCTTGGAGTGGGGAGA
CYP2D6_R ACTGAGCCCTGGGAGGTAGGTA
CYP2D7__Seq B1  GTCCCACACCAGGCACCTGTACT
CYP2D6_Rep 7R3  GAATTAGTGGTGGTGGGTGTTTG
CYP2D6_DUP_Fw CCATGGAAGCCCAGGACTGAGC
CYP2D7_DUP_Rv CGGCAGTGGTCAGCTAATGAC
CYP2D6_Fw_DUP_TOTAL CCAGAAGGCTTTGCAGGCTTCAG
CYP2D7_DUP_Rv CGGCAGTGGTCAGCTAATGAC
8,6
5,5
3,5
3,5
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PCR reactions were performed in a final volume of 10 µL, containing 3,5 µL of deionized 
water, 1 µL of 10x Advantage® Genomic LA Buffer (Clontech), 0.4 µL of Expand Long 
Range dNTP Pack (Roche Diagnostics GmbH), 1.2 µL of each primer, 0.1 µL of 
Advantage® Genomic LA Polymerase Mix (Clontech), 1 µL of Q-solution (Quiagen ®), 
in order to stabilize the PCR reaction and minimize non-specific amplification, and 1.6 
µL of DNA. The amplification conditions for the specific region approach were as follow: 
94 ºC for 3 minutes, proceeded by 2 cycles at 98 ºC for 15 sec, 68ºC for 6 min, another 
3 cycles at 98 ºC for 15 sec and 66 ºC for 6 min and another 30 cycles at 98 ºC for 15 
sec and 64 ºC for 6 min and a final extension at 72 ºC for 10 min. For the whole gene 
duplication were as follow: 94 ºC for 3 minutes, proceeded by 2 cycles at 98 ºC for 15 
sec, 68ºC for 8 min, another 3 cycles at 98 ºC for 15 sec and 66 ºC for 8 min and another 
30 cycles at 98 ºC for 15 sec and 64 ºC for 8 min and a final extension at 72 ºC for 10 
min. 
 The amplification reactions were conducted in 2720 Thermal Cycler (Applied 
Biosystems) or/and T100TM Thermal Cycler (BioRad).  
 
   
 2.1. Electrophoresis 
 
All PCR products were run in agarose electrophoresis (1.5%) in order to assess 
the success of the amplification reactions and the presence of possible contaminations. 
Images of the DNA bands in the agarose gel were acquired using the ChemidocTM XRS+ 
System, with the aid of Quantity One 1-D Analysis Software. 
 
 
3. SNP Genotyping 
 
 To obtain the genotyping data for SNPs (Figure 5), SNaPshotTM reactions were 
performed. 11 single base extension (SBE) primers were designed in a similar way for 
the amplification primers, only excepting that these end right before the target SNPs 
(Table 3). Primer sequences were identical to those described in Sistonen et al. (2005) 
(28). To promote differences in electrophoretic mobility, a non-annealing tail with different 
sizes was added to the SBE primers. 
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Before the SNaPshotTM reactions, a purification step was performed with 
ExoSAP-IT® in order to remove the surplus of dNTPs and primers present in the PCR 
product. Each reaction contained 1 µL of amplified product and ExoSAP-IT® and the 
thermocycler conditions used were 37ºC for 15 min and 85ºC for 15 min. A mix containing 
all SBE primers was prepared with the following primer quantities: 0,1 µL of the 1659 
G>A and 1846 G>A, 0,5 µL from the 4180 G>C and 0,2 µL for the remaining SNPs. The 
SNaPshotTM reactions were carried out in a final volume of 5,2 µL containing 2 µL of 
purified PCR product, 2,2 µL of SBE primer mix and 1 µL of SNaPshotTM Multiplex Kit 
(Applied Biosystems). The reaction conditions were 25 cycles at 96ºC for 10 sec, 50ºC 
for 5 sec and 60ºC for 30 sec. After this step, the products were treated with 1 µL of SAP 
enzyme (USB®) at 37ºC for 60 min and 85ºC for 15 min. All these reactions were 
performed in a 2720 Thermal Cycler (Applied Biosystems) and/or T100TM Thermal Cycler 
(BioRad). Lastly, 1 µL of the SNaPshotTM purified products were mixed with 12 µL of Hi-
DiTM Formamide (Applied Biosystems) and Gene-ScanTM – 120 LIZTM size standard. 
Capillary electrophoresis was then carried out in an ABI 3130 Genetic Analyser (Applied 
Biosystems). 
Table 3 - Primers used in the SNaPshotTM reactions. 
Figure 5 - Representation of the CYP2D6 exons and the different positions of the SNPs analysed. Each number (1-9) represents the position of each 
exon from 5’ to 3’. The primers used of each position are described in table 3. Adapted from Sistonen et al. (2005) 
100C>T rs1065852 ACGCTGGGCTGCACGCTAC
1023C>T rs28371706 ACCGCCCGCCTGTGCCCATCA
1659G>A rs61736512 CTGACAAGCGCGAGCAGAGGCGCTTCTCC
1707delT rs5030655 GCAAGAAGTCGCTGGAGCAG
1846G>A rs3892097 CCGCATCTCCCACCCCCA
2549delA rs35742686 GATGAGCTGCTAACTGAGCAC
2615delAAG rs5030656 GCCTTCCTGGCAGAGATGGAG
2850C>T rs16947 AGCTTCAATGATGAGAACCTG
2988G>A rs28371725 AGTGCAGGGGCCGAGGGAG
3183G>A rs59421388 TGTCCAACAGGAGATCGACGAC
4180G>C rs1135840 GTGTCTTTGCTTTCCTGGTGA
Polymorphism Rs Sequence 5´-3 '
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4. Sanger Sequencing 
 
The Sanger Sequencing method was used to confirm results from the 
SNaPshotTM reactions, using primers described in table 4. Initial purification was carried 
out on the amplification products as described in section 3. The sequencing reactions 
were performed in a final volume of 5 µL containing 2 µL of purified amplification product, 
1 µL of the amplification primer at 4 µM, 1 µL of BigDye® Terminator v3.1 Cycle 
Sequencing Kit and 1 µL of sequencing Buffer. The conditions used were as follow: 96ºC 
for 4 min, followed by 35 cycles at 96ºC for 10 sec, 55ºC for 5 sec and 60ºC for 4 min, 
and a final step at 60ºC for 10 min. The reactions were carried out in Thermal Cycler 
(Applied Biosystems) or/and T100TM Thermal Cycler (BioRad). After this, the sequencing 
products were purified in Sephadex® columns (760 µL) through centrifugation for 4 min 
at 4400 rpm. The final products were resuspended in 12 µL of Hi-DiTM Formamide and 
capillary electrophoresis was performed in an ABI 3130 Genetic Analyser (Applied 
Biosystems). 
 
 
 
 
 
 
 
 
 
 
 
 
NAME SEQUENCE 5 '-3 ' SNPs RANGED EXPECTED SIZE
CYP2D6_SEQ_1_F ATCTTCCTGCTCCTGGTGGAC 100C>T ~80 bp
CYP2D6_SEQ_2_F TTCAAATAGGACTAGGACCTGTA 1023C>T ~250bp
CYP2D6_SEQ_3_R GAATGTCCTTTCCCAAACCCAT 1659G>A; 1707delT; 1846G>A ~500 bp
CYP2D6_SEQ_4_F CACAGGAGGGATTGAGACCC 2549delA; 2615delAAG; 2850C>T; 2988G>A; 3183G>A ~800 bp
CYP2D6_SEQ_5_R TTATTGTACATTAGAGCCTCTGG 4180G>C ~100 bp
Table 4 - Primers used in the Sanger Sequencing reactions. 
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5. Data Analysis 
 
The results obtained in the SNaPshotTM reactions were analysed using the 
GeneMapper® v4.0 software and the sequencing data was analysed with Geneious Pro 
5.5.8. The Arlequin Software v3.5 was used to test for Linkage Disequilibrium (L.D.), 
estimate haplotype frequencies and to test deviations from the Hardy-Weinberg 
Equilibrium.  
In order to perform comparative analysis, data from previous works published 
was used (25, 30, 41). 
To evaluate the significance of the difference between the two proportions, the z-
ratio was calculated in the web site http://vassarstats.net/. 
 
 
IV. RESULTS AND DISCUSSION 
 
1. CYP2D6 Genotyping  
 
After applying the strategy to detect the presence of the entire CYP2D6 gene, 
positive results were observed in 55 of the 56 individuals tested. In the remaining subject, 
the suspicion of being homozygous for the deletion was confirmed through the strategy 
used to identify the deletion of the entire CYP2D6 gene, which was applied for all the 
samples in this study. In figure 6 is depicted an example of an agarose electrophoresis 
of different PCR products. As is illustrated, samples positive for the presence of the gene 
presented a band corresponding to the whole gene (marked arbitrarily as “G”). That band 
was absent in a unique individual (“X5” in Figure 6), who was also the unique presenting 
the band expected when submitted to the approach undertaken to test the gene deletion 
(marked as “X5 D”). 
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The 11-plex SNaPshotTM reaction was successfully developed and applied for all 
the 56 samples. In figure 7 are shown illustrative CYP2D6 electropherograms obtained 
for different individuals. The electropherogram at the bottom presented in the figure 
corresponds to the result observed for sample “X5”, identified as a homozygous for the 
gene deletion, which showed entire failure of the SNaPshotTM reaction, thereby 
consistent with a gene deletion on this sample. 
 Lastly, a molecular strategy directed to the identification of gene duplications was 
applied to the 55 samples positive for the presence of CYP2D6 (Figure 8), which allowed 
to identify 3 individuals possibly harbouring that kind of copy number variations. 
However, when the strategy used to validate the presence of the whole duplicated gene 
Figure 7 – Example of an electropherogram performed in this study and respective predicted genotype. The last one 
was obtained from the sample suspected to have a deletion of the whole gene, confirming our suspicion. 
Figure 6 – Example of an Agarose Electrophoresis performed for the analysis of the whole gene and cases of gene deletion. Lanes 1 and 
11- DNA molecular weight markers (Ladder 1 kb); Lanes 2 to 9 - samples amplified with the primers designed to detect the whole gene. 
Lanes 12 to 18 - the same samples amplified with the primers designed to detect deletion of the whole gene. Lanes 10 and 20 – Negative 
controls of the PCR reactions.  Sample in lane 8 doesn’t present any band when tested for the presence of the whole gene, but presents a 
band when tested for the deletion of the whole gene (Lane 18). Sample in lane 9 didn’t present any band after the two amplification 
approaches, due to poor quality of DNA.  
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was applied to these 3 individuals (Figure 9), only in one of them was observed a positive 
result, which was further confirmed after using the SNaPshotTM technique (Figure 10). 
Thus, a gene duplication was detected in a unique individual from the studied Roma 
sample.     
  
 
 
 
 
 
Figure 8 – Example of an agarose electrophoresis performed to determine the presence or not of 
duplication events. A control sample from the HGDP-CEPH (lane 1) was used as a positive control of the 
amplification. Sample in lane 10 presents a band identical to the positive control, indicating the presence 
of a duplication event. The bands presented in the remaining lanes (2-9) are due to non-specific 
amplification. 
Figure 9 – Example of an agarose electrophoresis performed to determine the presence of 
the whole duplicated gene. A control sample from the HGDP-CEPH (Lane 2) was used again 
as a positive control. In lane 1 is the negative control for the amplification. The 3 samples 
tested (lane 3-5) were those identified through a previous approach as suspected to have a 
gene duplication. Only one of them (lane 4) presented a positive result in the PCR assay 
specific for the detection of the whole duplicated gene. 
                                                                                                                                                  FCUP 36 
                                                  Updating the study of pharmacogenetic polymorphisms in the Portuguese Roma 
 
 
 
2.  Inference of CYP2D6 diplotypes 
 
 
Out of the 11 polymorphic positions screened in our sample, no variation was 
detected at 1023C>T, 1659 G>A, 1707 del, 2615 delAAG and 3183 G>A. For the 
remaining 6 polymorphisms, tests for Hardy-Weinberg equilibrium were performed 
Table 5 – Results from the Hardy – Weinberg equilibrium test obtained for the 11 positions 
Position n p - value s. d.
100 C>T 56 0.53450 0.00049
1023 C>T
1659 G>A
1707 delT
1846 G>A 56 1 0
2549 delA 56 1 0
2615 delAAG
2850 C>T 56 0.34462 0.00048
2988 G>A 56 1 0
3183 G>A
4180 G>C 56 0.00448 0.00007
Observable Heterozygosity Expected Heterozygosity
0.48214 0.43356
0.40851
0.13611
0.48440
Monomorphic
Monomorphic
Monomorphic
Monomorphic
Monomorphic
0.29091
0.14545
0.05354
0.41635
0.41818
0.05455
0.36364
Figure 10 – SNaPshotTM reaction performed to confirm the results of the whole duplicated gene approach. a) Control 
Sample HGDP00531; b) Sample with duplication identified in the present study. In the electropherogram of the control 
HGDP00531, known to have the genotype *2/*4N, the position 1846 is altered, presenting an A instead of a G, therefore 
indicative of the duplication event in the allele *4. In our sample, the electropherogram did not reveal alterations in the 
position 1846, as well as the remaining positions, therefore indicating that the duplicated gene harbors allele *1. 
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(Table 5), which uniquely revealed a significant departure between observed and 
expected genotypic distributions at 4180 G>C due to an excess of homozygotes 
(observed heterozygosity: 29,1%; expected: 48,4%), even after the Bonferroni correction 
for multiple tests was applied. 
 
   
 As expected, significant Linkage Disequilibrium (L.D.) was detected between the 
intergenic variations examined (Table 6).  Accordingly, from the unphased genotypic 
data, diplotypes were reconstructed for each individual using the EM algorithm 
implemented in Arlequin, which was also used to estimate frequencies for the inferred 
haplotypes.  
  
 
 
 
The program has inferred 13 distinct haplotypes in our sample, all of which 
corresponding to allelic variants or sub-variant already defined in the CYP Allele 
Nomenclature Database. 
Positions 100 C>T 1023 C>T 1659 G>A 1707 delT 1846 G>A 2549 delA 2615 delAAG 2850 C>T 2988 G>A 3183 G>A 4180 G>C
100 C>T * - - - + - - - - - +
1023 C>T - * - - - - - - - - -
1659 G>A - - * - - - - - - - -
1707 delT - - - * - - - - - - -
1846 G>A + - - - * + - + + - +
2549 delA - - - - + * - + + - +
2615 delAAG - - - - - - * - - - -
2850 C>T - - - - + + - * + - +
2988 G>A - - - - + + - + * - +
3183 G>A - - - - - - - - - * -
4180 G>C + - - - + + - + + - *
Table 6 – Results of Linkage Disequilibrium (L.D.) obtained for the 11 positions. Presence of L.D. (+); Absence of L.D. (-) 
Table 7 - Haplotypes defining different CYP2D6 alleles, corresponding effects in enzyme activity and frequencies in the Portuguese Roma. Note: 
Haplotype ID corresponds to the identifier provided by Arlequin, while the CYP2D6 allele designations and effects in enzyme activity were assigned 
according to the CYP Allele Nomenclature Database. 
1 T C G T A A AAG C G G C *4 None 0,238444 ± 0,0433
2 C C G T G A AAG C G G C *39 Normal 0,035977 ± 0,018525
3 T C G T A A AAG C G G G *4J None 0,009322 ± 0,009732
4 C C G T G A AAG C G G G *1 Normal 0,317943 ± 0,048101
5 T C G T G A AAG C G G C *10 Decreased 0,046051 ± 0,019395
6 C C G T G A AAG T G G C *2 Normal 0,179935 ± 0,040293
7 C C G T G G AAG C G G G *3 None 0,026786 ± 0,016723
8 C C G T G A AAG T A G C *41 Decreased 0,059859 ± 0,025156
9 C C G T G A AAG C A G G *41v Decreased 0,01157 ± 0,010385
10 C C G T G A AAG T G G G *34 Normal 0,027237 ± 0,018843
11 C C G T A A AAG C G G C *4M None 0,010337 ± 0,009338
12 T C G T A A AAG T G G C *4K None 0,018683 ± 0,01566
13 - - - - - - - - - - - *5 None 0,017857 ± 0,012943
Haplotype I.D 100 C>T 1023 C>T 1659 G>A 1707 del. T 1846 G>A 2549 del. A 2615 del. AAG 2850 C>T 2988 G>A 3183 G>A 4180 G>C CYP2D6 allele Enzyme Activity Frequency
                                                                                                                                                  FCUP 38 
                                                  Updating the study of pharmacogenetic polymorphisms in the Portuguese Roma 
 
  
 In table 7 are presented the detected alleles, their frequencies in the sample of 
Portuguese Roma and the effect of each allele in enzyme function. Allele CYP2D6*5, 
which refers to the deletion of the gene and consequently to a non-functional allele, was 
present in homozygosity in one individual.  No heterozygous for the deletion were found, 
although carriers could be identified with the methodological strategy used to detect this 
kind of copy number variation. Given that the frequency of CYP2D6*5 was 1,8%, the 
number of expected heterozygous in a sample of 56 individuals was 1,96, which is a 
considerably low value, likely explaining that by chance heterozygous were missing in 
the studied sample of Portuguese Roma. 
 
 Four other alleles were detected in the Roma that were associated to absence of 
enzymatic activity: CYP2D6*4 and its subtypes *4J, *4M and *4K, all bearing the splice 
site mutation 1846 G>A responsible for loss of activity, and CYP2D6*3, defined by 2549 
del.A, which is a frameshift mutation also responsible for a non-functional product. Taken 
together the alleles conferring none activity summed up 29,8 % in the sample. Two 
partially functioning variants were identified, CYP2D6*10 and CYP2D6*41, both leading 
to decreased enzymatic activity, that together were present at 11,7%. The remaining 
detected alleles were normal function variants, including CYP2D6*1, which was the 
commonest allele (30,4%), CYP2D6*2, *34 and *39.  In total, the normal alleles reached 
53.7% in the sample.  
 
 As mentioned, the analysis of copy number variation revealed the presence of 
gene duplications in 1 individual, whose inferred genotype based on the SNaPshotTM 
results was *1/*4. The approach used to amplify the whole gene duplication also 
permitted to conclude that the duplicated gene involved the allele *1 of the genotype 
*1/*4. Nevertheless, the approach does not allow to infer the number of gene copies 
present in the individual. 
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3.  Metabolic Profiles  
 
 In order to predict the theoretical metabolic profiles from the CYP2D6 genotypes, 
we followed the strategy previously described by Gaedigk et al. (25, 31). It is referred to 
as “Activity Score” System, according to which genotypes are categorized by the 
‘‘number of active genes’’, alleles are grouped based on their assumed functionality, 
active scores (AS) are assigned to each genotype and then ASs are translated into a 
phenotype prediction that include the traditional classification as PM, IM, EM, and UM. 
To calculate the AS, a value of 1 is assigned to normal alleles (i.e. *1, *2, *34, *39), 0.5 
for reduced – activity alleles (i.e. *10, *17), 0 for null variant alleles (i.e. *3, *3xN, *4, *4K, 
*3xN, *4xN, *5) and 2 for multiplications alleles like *1xN or 2*xN. Therefore, genotypes 
with AS=0, were considered PM, with AS = 0,5 were considered IM, with AS = 1-2 were 
considered EM and with AS≥2 were considered UM. 
 
In Table 8 are presented the frequencies of the CYP2D6 genotypes in the 
Portuguese Roma and their ascribed AS. For the three subjects known to harbour gene 
duplications, only one presented a real duplicated event, which was the individual with 
the genotype *1/*4, and the duplication event was in allele *1, but we still cannot infer 
the extent of the duplication. Because he had at least two active gene, it is possible to 
deduce that the active score is two or greater than two. In terms of predicted metabolic 
profiles, the categories poor and intermediate metabolizers can be excluded, but he 
might fall either in the group of extensive or ultra metabolizers, depending on the extent 
of the duplicated allele.  
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 Taking into account the ascribed ASs, the great majority of the Portuguese Roma 
were predicted to be extensive (83,9%) or intermediate metabolizers (5,4%) (Figure 11). 
However, a substantial proportion of 8,9% (Figure 11) was assigned to the category of 
poor metabolizers, giving thus a prediction of the proportion of Roma at high risk of 
experiencing adverse reactions when treated with drugs that are metabolized by 
CYP2D6.    
Table 8 - Frequencies of CYP2D6 genotypes in the Portuguese Roma population. 
Concerning the genotype referred to as *1xN/*4, since it was not possible to infer the 
number of gene copies, while knowing that the duplicated gene involved allele *1, its 
number of active genes and active score is at least 2 although it can be greater than 2. 
N – Duplication event 
*1/*1 7 2 2 0,1250
*1/*2 3 2 2 0,0536
*1/*3 3 1 1 0,0536
*1/*4 9 1 1 0,1607
*1/*4J 1 1 1 0,0179
*1/*34 1 2 2 0,0179
*1/*41 4 2 1,5 0,0714
*2/*2 3 2 2 0,0536
*2/*4 6 1 1 0,1071
*2/*10 3 2 1,5 0,0536
*2/*39 1 2 2 0,0179
*2/*41 1 2 1,5 0,0179
*4/*4 2 0 0 0,0357
*4/*4M 1 0 0 0,0179
*4K/*4K 1 0 0 0,0179
*4/*10 1 1 0,5 0,0179
*4/*39 3 1 1 0,0536
*4/*41 2 1 0,5 0,0357
*5/*5 1 0 0 0,0179
*10/*41 1 2 1 0,0179
*34/*34 1 2 2 0,0179
*1xN/*4 1 ≥ 2 ≥ 2 0,0179
Genotype n Active Genes Active Score Frequency
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 As stated before, while we could infer that only one individual presented a 
duplication, it was not possible to deduce the extent of the duplication event, which is the 
total of gene copies contained in the chromosome with the duplication. This individual 
has a minimum number of two CYP2D6 genes but in fact can have more than two copies, 
and so he is the unique candidate in the Roma sample that theoretically can be ultrarapid 
metabolizer. As follows, we can only anticipate that this metabolic category in the 
Portuguese Roma might range from 0 and the maximum frequency of 1,8%. Depending 
on that, the frequency of extensive metabolisers can also vary between the minimum 
estimate at 83.9% and a maximum of 85.7%, with the latter value registered if the 
individual is not ultra metabolizer. 
 
 
 
 
 
 
 
 
 
Figure 11 - Frequencies of theoretical metabolic profiles in the Portuguese Roma 
population. EM – Extensive Metabolizers; IM – Intermediate Metabolizers; PM – Poor 
Metabolizers; UM – Ultrarapid Metabolizers.  
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4.  Comparison with other populations 
 
 To put the data here obtained for the Portuguese Roma in a broad population 
context, we took advantage on a recently study that constitutes the most comprehensive 
work up to now performed summarizing CYP2D6 allele frequencies, diplotypes and 
predicted phenotype across major populations (25). The study was based on an 
exhaustive data compilation from the literature, which ended up with hundred entries for 
multiple ethnic groups and populations from different geographical regions, including two 
about the Portuguese previously studied for CYP2D6 (30, 41). 
 
 Among the many population entries in the work of Gaedigk et al. (2016), we 
selected a few to illustrate the distribution of CYP2D6 alleles in European and Asian 
populations, which are presented in Table 9, where are also included the results from 
the present study. 
 
 As we can notice, there are many alleles without information for most of the 
populations listed in Table 9. This is not a consequence of any bias arising from our 
selection criteria, but only the reflex of the variety of genotyping strategies used in 
different studies. Owing to the major contribution to the metabolism and 
biotransformation of numerous drugs, CYP2D6 is one of the pharmacogenes most 
extensively analysed, although based in genotyping assays that greatly varied between 
studies. Many examined a small number of variations within the gene, usually coinciding 
with the allelic variants most common and with a widespread distribution, and 
consequently several variants certainly escaped detection. This causes a problematic 
skewed distribution, falsely overestimating the frequency of the default allele, that is the 
allelic category in which are included all those alleles not bearing any of the variations 
examined. 
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 The default allele is usually assumed to be CYP2D6*1 also referred to as the 
“wild-type” allele, which might then encompass the “non-normal” alleles that could not be 
detected with the screened positions. In this work we used a CYP2D6 genotyping 
technique that allows the detection of 11 of the most relevant polymorphic positions in 
the gene covering the majority of the clinically important mutations (28). However, most 
of those positions were not included in previous conventional typing methods, not 
including those more recently developed or obviously those relying in high-throughput 
assays that are still very scarce (42, 43). This represented a setback regarding 
comparative statistical analysis. For instance, allele *41, which is a reduced - activity 
allele, is characterized by the presence of A instead of a G in position 2988, but also 
presents a T instead of a C in position 2850 and a C instead of a G in position 4180. 
Allele *2 is characterized by the presence of a T instead of a C in position 2850 and a C 
instead of a G in position 4180. If the SNP 2988 G>A is not analysed, we can misidentify 
an individual as *2/*2, when he could be *2/*41 or *41/*41. 
 
 Another issue in the comparative analysis was the difficulty to deal with 
multiplications. Although we developed a strategy to identify the allele duplicated, we 
could not infer the number of copies present with this approach. Therefore, and for the 
sake of simplicity, we have agglomerated the distinct types of multiplications reported in 
the populations considered in Table 9 in one single group, named “Multiplications”. 
 
 Regarding the set of normal alleles as a whole, including *1, *2, *34, *39 and 
“Others”, we can see that the Portuguese Roma present one of the lowest frequencies 
among Eurasian populations. For instance, comparatively to the host population, normal 
alleles summed up 71%, whereas the frequency in the Roma was substantially lower 
(56,1%), with the difference being statistically significant (P= 0,001 in the z-ratio for the 
significance of the difference between the two proportions). In compensation, the total 
frequency of defective alleles in the Portuguese Roma (32,1%) lies in the limit of the 
upper range of values until now reported. Focusing again in the comparison with the 
Portuguese host population, all defective alleles present in the Roma (*3, *4 and *5) are 
also present in the Portuguese host population. However, it is remarkable the increased 
frequency of the null allele CYP2D6*4 in the Roma (27,7%), comparatively to other 
Portuguese, among whom the frequency is considered below 20%. 
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 As for reduced – activity alleles, two variants are present in the Portuguese 
Roma: CYP2D6*10, with a frequency of 4,6% and CYP2D6*41, with a frequency of 7,1%. 
The first was also found in the Portuguese host population, while the second one was 
not screened up to now in other Portuguese. Both CYP2D6*10 and *41 are encountered 
in most other European populations, with a typical frequency range in which fall the 
values observed in the Portuguese Roma. Interestingly, CYP2D6*10 is very well 
represented in Indian populations, particularly from the North where it reaches 16.8%, 
as well is CYP2D6*41, at least in West India (12,5%), once it was not yet screened in 
other Indian populations. Actually, the distribution of latter allele is still very scarcely 
known because often it was not included in the CYP2D6 typing methods. The highest 
frequency up to now reported in Europe was among Austrians, attaining 12.4%, thus a 
value similar to the reported for Western Indians. 
 
 Data for CYP2D6 was available for a Roma group from Hungary (Table 9), 
although based on a panel of variations with low resolution, and so only allowed to 
identify the alleles CYP2D6*4 and *10, two variants we found in the Portuguese Roma, 
but also widespread in other populations. However, a finding that deserves attention is 
the high frequency of CYP2D6*4 in the Hungarian Roma (22,5%), though lower than 
among the Portuguese Roma (27,7%) as well as the very high proportion of CYP2D6*10 
(26.6%).  In non-Roma European populations, very rarely CYP2D6*4 exceeds 20% (two 
unique reports in the Swedish, 24.4%, and, suggestively, in the Hungarian non-Roma, 
20.4%), while the values of CYP2D6*10 in Europe are usually lower than 5%. The 
atypically increased frequencies of some CYP2D6 alleles in the Portuguese and 
Hungarian Roma, is fully consistent with what is known about the demographic history 
of Roma groups, which along time was always accompanied by remarkable founder 
events.  
  
 In respect to the multiplications, we can see that the frequency of 1.8% in the 
Portuguese fits well the values reported for other populations. Notably, the distribution of 
multiplications across populations is quite uniform. 
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 In terms of metabolic profiles, we recall that the inferred theoretical categorization 
in the Portuguese Roma was 83.9% for EM, 5.4% for IM, 8.9% for PM and 1.8% still 
partially unknown, which can only fall in EM or UM, but for the sake of comparative 
analysis, we decided to consider it UM.  In order to compare this profile with that from 
the Portuguese non-Roma, we applied the same criteria to the raw data presented by 
Albuquerque et al, which has yielded the following proportions: 88.7% for EM, 0.7% for 
IM, 6.3% for PMs and 4.3% for UM. Figure 12 shows the profiles of the Portuguese Roma 
and non-Roma, which despite not differing too much, reveal that the proportion of PMs 
in the Roma is slightly higher than in non-Roma, but the difference is not statistically 
significant (P=0.228), and that the proportion of IM in the Roma is also higher than in 
non-Roma, but in this category difference reaches statistical significance (P=0.006). This 
is due to elevated frequency of null variant alleles detected in the Portuguese Roma, 
namely alleles *4 and *10, which have contributed to diminish the frequency of EMs at 
the cost of increased frequency of PMs plus IMs individuals. 
 
 
 
 
 
 
 
 
 
Figure 12 - Frequencies of theoretical metabolic profiles. a) Portuguese Roma (current study); b) Portuguese host (Albuquerque et al. 2013). 
EM – Extensive Metabolizers; IM – Intermediate Metabolizers; PM – Poor Metabolizers; UM – Ultrarapid Metabolizers; 
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V. FINAL REMARKS 
 
 In this study we have applied a high resolution SNaPshotTM methodology to 
characterize CYP2D6 in a sample of Portuguese Roma.  
 
 The results obtained led to conclude that when Portuguese Roma are submitted 
to treatments with drugs in which CYP2D6 acts in the biotransformation, they likely will 
be more susceptible to adverse drug reactions than other Portuguese, because they 
have higher frequencies of null CYP2D6 alleles. And this is where, like it has been 
discussed throughout the years, pharmacogenetic will have a preponderant role in 
clinical practice. With the improvement and introduction of genetic test in the clinical 
setting, there will be the possibility of developing the so called “Personalized Medicine”, 
which will give the physician the tools needed to not only prescribe the right dose of the 
drug necessary, but also monitor the response of the patient throughout the treatment. 
Expectation are growing with the raise of high-throughput genomic approaches. 
Respecting CYP2D6 micro-chip/array analysis is already often applied, it has some 
disadvantages because this methodology cannot discriminate accurately the number of 
active genes, which is critical in cases of UM individuals (30). Next generation 
sequencing is a powerful tool, but was also demonstrated to be problematic in the 
analyses of CYP genes. Therefore, there is an imperative need to develop a more 
reliable, efficient and cost – effective method, in order to be more commonly used in 
clinical practice. There has been some works developed in that way, mainly through the 
use of WGS (Whole – Genome Sequencing). This method has been successfully applied 
to the molecular diagnosis of genetic diseases, particularly in a clinical paediatric context, 
in cases of neurodevelopment disorders, to diagnose suspected underlying genetic 
diseases (43). Although we are still far of recommending WGS as the platform for routine 
pharmacogenetic testing, a study was already published by Twist et al. (42), reporting 
the development of a “computational method for automated derivation of diploid 
functional haplotypes from unphased WGS” for the CYP2D6 gene, designated as 
“Constellation”, which allows to detect all gene variants, including gene conversions and 
rearrangements. Nevertheless, the method encountered some setbacks as, for instance, 
it cannot consistently detect some rare variants like CYP2D6*68+*4, a tandem 
arrangement featuring a hybrid CYP2D6 / CYP2D7 gene upstream of a nonfunctional 
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CYP2D6*4. Despite the many works and efforts towards the implementation of 
pharmacogenetics in clinical practice, its application is still somehow new.  
 
 Another issue that needs further investigation is the correlation between the 
predicted metabolic profiles and levels of enzymatic activity assessed through 
biochemical assays. Although strong correlations have been reported mainly for 
European populations, given the complexity of the variations in CYP2D6, more studies 
are still needed to validate inferences based on genotypic data and avoid thus 
misidentification of metabolic categories. For instance, an individual predicted to be EM, 
might have an unsuspected and so unscreened null variant allele causing decrease of 
enzyme activity, which would escape detection by conventional genotypic analysis. 
 
 With the development of this study, even though our primary goal was to explore 
the knowledge regarding allelic frequencies and theoretical metabolic profiles at the 
CYP2D6 gene in the Portuguese Roma, we also intend to aware to the impact that 
pharmacogenetics can have in clinical practice and that there is a great need to improve 
on this field. The implementation of Pharmacogenetics in the clinical setting cannot 
exempt the individualization of genetic tests. However, the knowledge of the specificities 
of groups like the Roma might alert for the need to rethink dedicated measures in terms 
of health care. 
 
   
  
 
 
 
 
 
 
  
                                                                                                                                                  FCUP 49 
                                                  Updating the study of pharmacogenetic polymorphisms in the Portuguese Roma 
VI. BIBLIOGRAPHY 
 
1. Abrahams E. Letter from the Executive Director: Latest News & Updates from the 
Personalized Medicine Coalition. Personalized Medicine. 2009;6:245. 
 
2. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the 
clinical geneticist? Clinical Genetics. 1999;56:247-258. 
 
3. Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug 
monitoring: a systematic review. Therapeutic Drug Monitoring. 2005;27:10-17. 
 
4. Berm EJ, Looff M, Wilffert B, Boersma C, Annemans L, Vegter S, et al. Economic 
Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. 
Second Update of the Literature. PloS one. 2016;11:e0146262. 
 
5. Cascorbi I, Bruhn O, Werk AN. Challenges in pharmacogenetics. European Journal of 
Clinical Pharmacology. 2013;69:17-23. 
 
6. Ma Q, Lu AYH. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. 
Pharmacological Reviews. 2011;63:437-459. 
 
7. Fonseca S, Amorim A, Costa HA, Franco J, Porto MJ, Santos JC, et al. Sequencing CYP2D6 
for the detection of poor-metabolizers in post-mortem blood samples with tramadol. Forensic 
Science International. 2016;265:153-159. 
 
8. Musshoff F, Stamer UM, Madea B. Pharmacogenetics and forensic toxicology. Forensic 
Science International 2010;203:53-62. 
 
9. Gladding PA. Clinical applications of pharmacogenetics: present and near future. 
Cleveland Clinical Journal of Medicine. 2013;80:477-482. 
 
10. Johnson JA, Burkley BM, Langaee TY, Clare-Salzler MJ, Klein TE, Altman RB. 
Implementing Personalized Medicine: Development of a Cost-Effective Customized 
Pharmacogenetics Genotyping Array. Clinical Pharmacology & Therapeutics. 2012;92:437-439. 
 
11. Ross S, Anand SS, Joseph P, Paré G. Promises and challenges of pharmacogenetics: an 
overview of study design, methodological and statistical issues. JRSM Cardiovascular Disease. 
2012;1. 
 
12. Kupiec TC, Raj V, Vu N. Pharmacogenomics for the Forensic Toxicologist. Journal of 
Analytical Toxicology. 2006;30:65-72. 
 
13. Shabaruddin FH, Fleeman ND, Payne K. Economic evaluations of personalized medicine: 
existing challenges and current developments. Pharmacogenomics and Personalized Medicine. 
2015;8:115-126. 
 
14. Timbrell JA, Marrs TC. Biotransformation of Xenobiotics.  General, Applied and Systems 
Toxicology: John Wiley & Sons, Ltd; 2009. 
                                                                                                                                                  FCUP 50 
                                                  Updating the study of pharmacogenetic polymorphisms in the Portuguese Roma 
15. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of 
gene expression, enzyme activities, and impact of genetic variation. Pharmacology & 
Therapeutics. 2013;138:103-141. 
 
16. Wang H, LeCluyse EL. Role of Orphan Nuclear Receptors in the Regulation of Drug-
Metabolising Enzymes. Clinical Pharmacokinetics. 2003;42:1331-1357. 
 
17. Xu C, Li CY-T, Kong A-NT. Induction of phase I, II and III drug metabolism/transport by 
xenobiotics. Archives of Pharmacal Research. 2005;28:249-268. 
 
18. Jakoby WB, Ziegler DM. The enzymes of detoxication. Journal of Biological Chemistry. 
1990;265:20715-20718. 
 
19. Pilgrim JL, Gerostamoulos D, Drummer OH. Review: Pharmacogenetic aspects of the 
effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, 
interactions, and adverse effects. Forensic Science, Medicine, and Pathology. 2011;7:162-184. 
 
20. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. 
The AAPS Journal. 2006;8:E101-E11. 
 
21. McKinnon RA. Cytochrome P450 1. Multiplicity and Function. The Australian Journal of 
Hospital Pharmacy. 2000;30:54-56. 
 
22. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature 
website: a peer-reviewed database of CYP variants and their associated effects. Human 
Genomics. 2010;4:278-281. 
 
23. Sim SC, Miller WL, Zhong XB, Arlt W, Ogata T, Ding X, et al. Nomenclature for alleles of 
the cytochrome P450 oxidoreductase gene. Pharmacogenetics and Genomics. 2009;19:565-566. 
 
24. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in 
drug therapy: the past, present and future. Trends in Pharmacological Sciences. 2004;25:193-
200. 
 
25. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 
phenotype from genotype across world populations. Genetics in Medicine. 2016. 
 
26. He Z-X, Chen X-W, Zhou Z-W, Zhou S-F. Impact of physiological, pathological and 
environmental factors on the expression and activity of human cytochrome P450 2D6 and 
implications in precision medicine. Drug Metabolism Reviews. 2015;47:470-519. 
 
27. Indiana, University. P450 Drug Interactions Abbreviated "Clinically Relevant" Table 
Department of Medicine - Indiana University, USA2016 [cited 2016]. Available from: 
http://medicine.iupui.edu/clinpharm/ddis/clinical-table. 
28. Sistonen J, Fuselli S, Levo A, Sajantila A. CYP2D6 genotyping by a multiplex primer 
extension reaction. Clinical Chemistry. 2005;51:1291-1295. 
 
29. Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, et al. 
Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication 
events. Clinical Pharmacology and Therapeutics. 2007;81:242-251. 
                                                                                                                                                  FCUP 51 
                                                  Updating the study of pharmacogenetic polymorphisms in the Portuguese Roma 
30. Albuquerque J, Ribeiro C, Naranjo MEG, Llerena A, Grazina M. Characterization of 
CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic 
implications. Personalized Medicine. 2013;10:709-18. 
 
31. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 
Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype. 
Clinical Pharmacology & Therapeutics. 2008;83:234-242. 
 
32. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide 
genetic variation shows high frequency of altered activity variants and no continental structure. 
Pharmacogenet Genomics. 2007;17:93-101. 
 
33. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, et al. The importance of race 
and ethnic background in biomedical research and clinical practice. The New England Journal of 
Medicine. 2003;348:1170-1175. 
 
34. Moorjani P, Patterson N, Loh P-R, Lipson M, Kisfali P, Melegh BI, et al. Reconstructing 
Roma History from Genome-Wide Data. PLoS ONE. 2013;8:e58633. 
 
35. IovitĄ̆ RP, Schurr TG. Reconstructing the Origins and Migrations of Diasporic 
Populations: The Case of the European Gypsies. American Anthropologist. 2004;106:267-281. 
 
36. Mendizabal I, Valente C, Gusmao A, Alves C, Gomes V, Goios A, et al. Reconstructing the 
Indian origin and dispersal of the European Roma: a maternal genetic perspective. PloS one. 
2011;6:e15988. 
 
37. Regueiro M, Rivera L, Chennakrishnaiah S, Popovic B, Andjus S, Milasin J, et al. Ancestral 
modal Y-STR haplotype shared among Romani and South Indian populations. Gene. 
2012;504:296-302. 
 
38. Teixeira J, Amorim A, J. Prata M, Quental S. Pharmacogenetic Polymorphisms in a 
Portuguese Gypsy Population. Current Pharmacogenomics and Personalized Medicine. 
2015;13:36-40. 
 
39. Lareu MV, Phillips CP, Carracedo A, Lincoln PJ, Syndercombe Court D, Thomson JA. 
Investigation of the STR locus HUMTH01 using PCR and two electrophoresis formats: UK and 
Galician Caucasian population surveys and usefulness in paternity investigations. Forensic 
Science International. 1994;66:41-52. 
 
40. Kramer WE, Walker DL, O'Kane DJ, Mrazek DA, Fisher PK, Dukek BA, et al. CYP2D6: novel 
genomic structures and alleles. Pharmacogenetics and Genomics. 2009;19:813-822. 
 
41. Correia C, Santos P, Coutinho AM, Vicente AM. Characterization of pharmacogenetically 
relevant CYP2D6 and ABCB1 gene polymorphisms in a Portuguese population sample. Cell 
Biochemistry and Function. 2009;27:251-255. 
 
42. Twist GP, Gaedigk A, Miller NA, Farrow EG, Willig LK, Dinwiddie DL, et al. Constellation: 
a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, 
CYP2D6, from whole-genome sequences. Npj Genomic Medicine. 2016;1:15007. 
 
                                                                                                                                                  FCUP 52 
                                                  Updating the study of pharmacogenetic polymorphisms in the Portuguese Roma 
43. Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, 
Newsham I, et al. Whole-Genome Sequencing for Optimized Patient Management. Science 
Translational Medicine. 2011;3:87re3-re3. 
 
